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 Abstract 
 
Rat umbilical cord matrix stem cells (UCMSC) have been shown to exhibit a remarkable 
ability to control rat mammary adenocarcinoma (Mat B III) cell proliferation both in vivo and in 
vitro. To study the underlying mechanisms and genes involved in Mat B III growth attenuation, 
total RNA was extracted from the naïve rat UCMSC alone and those co-cultured with Mat B III 
in Transwell culture dishes. Gene expression profiles of naive rat UCMSC alone and those co-
cultured with Mat B III cells were investigated by microarray analysis using an Illumina RatRef-
12 Expression BeadChip. The comparison of gene expression profiles between untreated and co-
cultured rat UCMSC identified five up-regulated candidate genes (follistatin (FST), sulfatase1 
(SULF-1), glucose phosphate isomerase (GPI), HtrA serine peptidase (HTRA1), and adipocyte 
differentiation-related protein (ADRP)) and two down-regulated candidate genes (transforming 
growth factor, beta-induced, 68kDa (TGFβI) and podoplanin (PDPN)) based upon the following 
screening criteria: 1) expression of the candidate genes should show at least a 1.5 fold change in 
rat UCMSC co-cultured with Mat B III cells; 2) candidate genes encode secretory proteins; and 
3) they encode cell growth-related proteins. Following confirmation of gene expression by real 
time-PCR, ADRP, SULF-1 and GPI were selected for further analysis. Addition of specific 
neutralizing antibodies against these three gene products individually in co-cultures of 1:20 rat 
UCMSC:Mat B III cells significantly increased cell proliferation, implying that these gene 
products are produced under the co-cultured condition and functionally attenuate cell growth. 
Immunoprecipitation followed by Western blot analysis demonstrated that these proteins are 
indeed secreted into the culture medium. Individual over-expression of these three genes in rat 
UCMSC significantly enhanced UCMSC-dependent inhibition of cell proliferation in co-culture. 
 These results suggest that ADRP, SULF-1 and GPI act as tumor suppressor genes, and these 
genes might be involved in rat UCMSC-dependent growth attenuation of rat mammary tumors. 
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CHAPTER 1 - Introduction 
	  Breast	  cancer	  continues	  to	  be	  one	  of	  the	  most	  common	  cancers	  and	  a	  major	  cause	  of	  death	  among	  women	  worldwide[1]. Breast cancer occurs when mammary epithelial cells 
multiply uncontrollably, causing damage to the mammary gland function and interfering with the 
normal function of other organs by metastasis[2]. The most common types of breast cancer are 
ductal and lobular carcinoma[3]. Other less common types of breast cancer include inflammatory 
breast cancer characterized by general inflammation of the mammary epithelium, medullary 
carcinoma (an invasive breast carcinoma that forms a distinct boundary between tumor tissue 
and normal tissue), mucinous carcinoma (formed	  by	  the	  mucus-­‐producing	  cancer	  cells), and 
tubular carcinoma (cancer that begins inside the milk duct and spreads beyond it)[3].	  
Current statistics of breast cancer  
 
Breast cancer is second only to lung cancer as the leading cause of cancer deaths among 
women in the United States of America (USA) with higher incidence rates than any other cancer 
type[4] . Breast cancer will affect one of every eight American women in their lifetime. 
American Cancer Society estimation for breast cancer incidence in USA for 2010 is about 
207,090 for females and 1,970 for males and estimated numbers of deaths are 39,840 for females 
and 390 for males.  
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Figure 1.1. The incidence and mortality of cancers in the USA[4].  
A. Incidence of top 10 types of cancers in the United States. Breast cancer is the highest among 
the all cancers. B. The mortality rates of the top 10 cancers in the United States. Breast cancer 
ranked second among cancer mortality rates with a rate equaling those of colorectal cancer and 
pancreatic cancer combined. 
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Current breast cancer therapies 
 
Currently, available clinical therapies for breast cancer include surgical resection, 
radiation therapy, hormone therapy, and chemotherapy[5]. Surgical resection is usually the most 
common and first line of therapy for breast cancer, Lumpectomy (breast-sparing surgery) and 
mastectomy are the two types of surgical therapies[6]. Radiation therapy uses ionizing (high-
energy) radiation to kill the tumor cells and this procedure generally reduces the risk of breast 
cancer recurrence by approximately 70%[5, 7]. However, it often induces adverse side effects on 
normal tissues adjacent to the radiation site[5]. For both of the above therapies the tumor should 
be within clinical detection range and accessible to therapeutic procedures[5]. 
Chemotherapy is a major post-surgical treatment used to reduce the risk of cancer 
recurrence[5]. Chemotherapy decreases the tumor size by affecting rapidly dividing and highly 
metabolizing cells, which are the main characteristics of malignant cells[5]. Generally, 
chemotherapy involves the administration of drugs systemically through the bloodstream[5]. A 
large number of chemotherapeutics are clinically available. In many cases, a combination of two 
or more drugs will be used as a treatment regimen for breast cancer[5]. However, chemotherapy 
causes side effects like hair loss (alopecia), fatigue, anemia etc., by acting on dividing cells and 
cells, which have high metabolic activities[8]. 
Estrogen and progesterone promote breast cancer growth by affecting the mammary 
epithelial cells’ multiplying ability[9]. Hormone therapy prevents breast cancer cells from 
utilizing these hormones but it is not effective against hormone-receptor-negative breast cancers 
(mostly used as adjuvant therapies with other therapies)[10, 11]. The drugs that will block the 
synthesis of estrogen like anastozole, letrozole (aromatase inhibitors), leuprolide acetate, 
goserelin acetate (LH-RH agonists), and estrogen receptor modulators like tamoxifen (estrogen 
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receptor downregulator) are in use as therapeutic agents in hormonal therapy[9]. Although these 
drugs have been used successfully, they exhibit serious side effects such as blood clots, strokes, 
uterine cancer, cataracts, thinning bones and increase in blood cholesterol level[8]. Trastuzumab 
and Lapatinib are the other two cancer-related protein-targeted drugs that have been shown to be 
effective for breast tumors expressing high levels of HER2 (Human epidermal growth factor 
receptor 2)[12].  
Among these therapies, a breast cancer target therapy is effective in treating a particular 
subset of breast cancer and exhibits fewer side effects[13]. However, only a small portion of 
breast cancer patients receives this benefit since targeting cancer–specific abnormal protein is not 
always an effective method of treating breast cancer[13]. Accordingly, chemotherapy and/or 
radiation therapy along with surgical resection is still the most important treatment regimen[5]. 
Although these therapies listed above effectively treat breast cancer, once again, their adverse 
side effects are a big hampering issue. For the staggering therapy-related side effects and 
mortality rates of breast cancer are to be reduced, novel therapies which exclude the serious side 
effects of current treatments are needed. Several new therapies based on biological agents such 
as nanoparticle drug delivery, stem cell based anticancer therapy, photodynamic therapy, 
targeted antibody therapy, and cancer vaccines, which are currently in development, have been 
very effective in preclinical research, but they have not yet been shown to be effective in clinical 
trials. Accordingly, a novel powerful cancer therapy with fewer side effects is urgently needed.  
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Postnatal stem cells and cancer therapy   
 
Postnatal stem cells or adult stem cells are undifferentiated cells found in tissues and 
organs, which have the ability to self-replicate [14]. These cells help in the maintenance of 
homeostasis in adult tissues by differentiating into different specialized cells [14, 15]. These cells 
have been identified in many organs and tissues like bone marrow (hematopoietic stem cells and 
bone marrow mesenchymal stem cells), skin, teeth, gut, liver, brain, blood, adipose tissue and 
umbilical cord blood and matrix. Among these stem cells, hematopoietic stem cells and bone 
marrow mesenchymal stem cells have been used in order to apply more intensive 
chemotherapeutic regimens [16]. However, these trials have yet to be successful.  
Apart from supplemental therapeutic use, some of the adult stem cells have tumor tropic 
property, which can be applied for the purpose of anticancer therapy [17-20]. Hall et al., showed 
that bone marrow-derived mesenchymal stem cells (MSCs) can migrate to the tumors and 
produce biological agents locally at tumor sites [21]. The tumor microenvironment preferentially 
promotes the engraftment of MSCs as compared with other tissues. MSCs engineered to over-
express IFN-β inhibited the growth of malignant cells in vivo [20, 22]. Importantly, this effect 
requires the integration of MSCs into the tumors and could not be achieved by systemically 
delivered IFN-β or by IFN-β produced by MSCs at a site distant from the tumors. This may 
indicate that MSCs may serve as a platform for delivery of biological agents in tumors. 
Recently, Dwain et al. and Aboody et al., showed that intravascular injections of neural 
stem cells (NSCs) may lead to preferential migration towards central nervous system tumors [17, 
23]. They have also demonstrated that, upon transplantation, genetically modified NSCs 
engineered to produce antitumor molecules have the ability to migrate towards tumors and 
reduce tumor mass directly or through a “bystander” effect. Modifying NSCs with either 
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endogenous promoters or viral vectors to express antitumor genes could be useful and practical 
for potential therapeutic use for brain tumors. NSCs modified to secrete HER2-targeting 
antibodies constitute a promising novel platform for targeted cancer immunotherapy [24]. 
Specifically, this NSC-mediated antibody delivery system has the potential to significantly 
improve clinical outcome for patients with HER2-overexpressing breast cancer [24]. 
Adipose-derived stem cells (ADSCs) are shown to possess the ability to home and deliver 
oncolytic myxoma virus (preferentially infects and lyse cancer cells) to gliomas xenografts [25]. 
In orthotopic xenograft studies, vMyxgfp transduced ADSCs injected intracranially distant from 
the tumor demonstrated that myxoma virus was delivered to tumor site by ADSCs and resulting 
in significant survival increase [25]. This result suggests that ADSCs are promising new carriers 
for oncolytic viruses, specifically myxoma virus, to brain tumors [19, 25]. Thus, adult stem cells 
hold a great promise for application in targeted anticancer therapy due to their unique tumor 
tropic characteristics. 
Umbilical cord matrix stem cells 
 
Umbilical cord matrix (Wharton’s jelly) is a rich source of mesenchymal like stem cells. 
Unlike with embryonic stem cells, the destruction of an embryo is not involved in the collecting 
of umbilical cord matrix stem cells [26]. Studies have demonstrated that UCMSC can be 
differentiated into a variety of specialized tissues such as nerve, liver, heart, kidney, bone 
marrow, and cartilage cells [26-30]. The additional fact that umbilical cords would normally be 
discarded after a healthy birth makes such stem cells readily, easily and inexpensively available 
worldwide. This offers a further advantage since, unlike with embryonic stem cells, UCMSC are 
ethically and politically noncontroversial. 
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UCMSC have been shown to be effective in the treatment of stroke, spinal cord damage, 
myocardial infarction, diabetes, retinal disease, Ischemia, liver disease, parkinson’s disease, etc 
[31-35]. Apart from these applications, UCMSC has tumor tropic properties [18, 36-40]. 
Although the exact signals that are recruiting UCMSC to the tumor area is still unknown, the 
same signaling process that is attracting the immune cells and MSCs to the neoplasia site may 
also be working for the tropism of UCMSC. 
Because of the inflammatory state in invasive tumors, stem cells may migrate towards 
tumors by chemo-attraction mechanisms. Several groups have showed the tumor tropic 
properties of UCMSC from human [36, 38, 39, 41] and rat [18, 37]. Ganta et al. has shown that 
un-engineered rat UCMSC alone significantly attenuate growth of rat mammary carcinoma in 
F344 rats without any evidence of reoccurrence [18]. The tumor regression effect of the rat 
UCMSC is dose dependent and these cells did not show any significant acute side effects [18]. 
These results strongly suggest that un-engineered rat UCMSC is an ideal therapeutic tool for the 
treatment of breast tumors. Finding the underlying molecular mechanisms and potential genes 
involved in rat UCMSC-dependent tumor growth attenuation will help to develop human 
UCMSC-based therapy for human cancer patients.  
Microarrays 
 
DNA microarray is one of the most powerful technologies to screen up-regulated or 
down-regulated genes in various pathophysiological conditions. Defining gene expression 
profiles, i.e. comparing patterns of gene expression in different tissues, developmental stages, in 
normal and disease states, or in distinct in vitro conditions, is a big step toward understanding the 
roles of various genes. Using DNA microarrays, a single hybridization experiment can generate a 
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genome-wide gene expression profile at once[48]. While gene expression profiling is currently 
the dominant microarray application, microarrays is also increasingly being used in the research 
of pharmacogenomics and molecular diagnostics[49]. Therefore, the range of microarray 
technology applications is enormous. A DNA microarray uses an orderly arranged known DNA 
probes attached to a solid support[48]. These samples can be partial oligonucleotides of cDNAs. 
RNA is isolated from various tissues or cells, reverse transcribed into cDNA and futher into 
cRNA and labeled by biotin. Then it is hybridized on a microarray chips/plates, stained with 
streptavidin and visualized by multiple techniques.  
Cancer is caused by repeating mutations of various genes such as tumor suppressor 
genes, oncogenes, genes related with cell cycle regulation, apoptosis, DNA repair, etc. 
Therefore, DNA microarray data might be one of the clues to uncover the basic biology, 
diagnosis, treatment of different cancers and shedding light on the uncountable questions about 
this problematic disease. Because our colleagues have shown that rat UCMSC have a potent 
ability to suppress the growth of Mat B III cells in vitro and in vivo[18]. DNA microarray would 
be the simplest and appropriate way to discover potential genes responsible for the tumoricidal 
function in rat UCMSC. 
Objective of project and experimental design 
 
Our colleagues, Ganta et al., showed that un-engineered rat UCMSC significantly 
regressed mammary carcinoma xenografts in F344 rats without reoccurrence for 100 days[18]. 
Ayuzawa et al. have discovered that naïve human UCMSC attenuate the growth of metastatic 
breast carcinoma xenografts in SCID mice [36]. Doi et al. have reported that a treatment with un-
engineered rat UCMSC significantly attenuated the growth of peritoneal xenografts of pancreatic 
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tumors and increased survival time of pancreatic tumor-bearing mice [37]. There are now 
compelling evidences that human UCMSC can be used as cancer-targeted gene delivery 
vehicles. Naive rat and human UCMSC that are not engineered to secrete therapeutic proteins 
also exert a potent anticancer effect in preclinical models [18, 36, and 37]. 
Identifying underlying molecular mechanisms of tumor growth attenuation or intrinsic 
tumoricidal genes of rat UCMSC helps to understand how rat UCMSC are regressing the 
neoplasm and this mechanisms may be utilized to develop novel treatment procedures for breast 
cancer. The present study is designed to identify the intrinsic tumor growth attenuating 
mechanisms of un-engineered rat UCMSC. For this purpose, rat UCMSC gene expression 
profiles in the presence and absence of Mat B III rat mammary carcinoma cells were analyzed 
using microarray analysis. Functions of screened candidate genes for intrinsic tumor growth 
attenuation by rat UCMSC were analyzed using [3H] thymidine uptake cell proliferation assay 
and the effect of neutralizing antibodies against selected gene products (proteins) on the cell 
proliferation. The present study clearly indicates that multiple tumor suppressor genes were up-
regulated in the rat UCMSC co-cultured with Mat B III cells. These gene products were 
determined to be functional in attenuation of the growth of Mat B III mammary carcinoma cells. 
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CHAPTER 2 - Materials & Methods  
Cell culture 
 
The rat UCMSC were maintained in low-serum defined medium containing the following 
mixture per 100 mL: 57 mL low-glucose DMEM (Invitrogen, Carlsbad, CA), 37 mL MCBD 201 
(Sigma, St Louis, MO), 2 mL fetal bovine serum (FBS; Atlanta Biologicals Inc.,Georgia), 1 mL 
of 100× insulin-transferrin-selenium-X (Invitrogen, Carlsbad, CA); 1 mL of 0.15 g/mL 
AlbuMax1 (Invitrogen, Carlsbad, CA), 1 mL of 100× Pen/Strep (Invitrogen,Carlsbad, CA), 10 
nmol/L dexamethasone (Sigma, St Louis, MO), 100 µmol/L ascorbic acid 2-phosphate (Sigma, 
St Louis, MO), 10 ng/mL epidermal growth factor (R&D systems, Minneapolis, MN), and 10 
ng/mL platelet derived growth factor-BB (R&D systems, Minneapolis, MN). Mat B III rat 
mammary adenocarcinoma line (ATCC, Manassas, VA), was maintained in McCoy's 5A 
modified medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 100 units/mL 
penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA).Primary  rat uterus 
fibroblasts (RUF) from Fisher 344 rat pups were prepared following an established method [50]. 
RUF were cultured in DMEM/Ham’s F-12 medium (1:1) supplemented with 10% FBS, 100 
units/ml pencillin, and 100 µg/mL streptomycin. All cells were cultured at 37°C in a humidified 
atmosphere containing 5% CO2. 
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Antibodies 
 
Rabbit and goat polyclonal antibodies against Adipose differentiation-related protein 
(ADRP), Sulfatase-1 (SULF1), Glucose phosphate isomerase (GPI), Podoplanin (PDPN), 
Decorin and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA).Horseradish peroxidase-conjugated anti-rabbit, anti-
goat IgG antibodies were obtained from GE Healthcare Bioscience Corp (Piscataway, NJ) and 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Co-culture of rat UCMS cells with Mat B III cells and RNA isolation 
 
Indirect co-culture of rat UCMSC (1 × 105 cells/dish) with Mat B III cells (1.5 × 106 
cells/dish) were carried out by using a Transwell cell culture system(Corning Life sciences, 
Lowell, MA), which allows free diffusion of substances without contact between tumor cells and 
stem cells. Mat B III cells were cultured in a Transwell insert with porous membrane (10 cm in 
diameter; pore size: 0.4µm), and rat UCMSC were maintained in the bottom culture dish using 
defined medium. Total RNAs were isolated from the rat UCMSC co-cultured with or without 
Mat B III cells and from Mat B III cells in the Transwell insert using Trizol (Invitrogen) 
according to the manufacturer’s protocols. The concentration and quality of the samples were 
measured by the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA) and 
Agilent 2100 bioanalyzer (Agilent Technologies, inc. Santa Clara, CA) respectively.  
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Microarray analysis procedures 
 
Microarray experiments including RNA quality evaluation, hybridization, and initial data 
analysis were carried out by Drs. Zhang, Becker, and Mr. Wood III at National Institute of 
Aging, National Institute of Health, (Baltimore, MD). For each sample, biotinylated cRNAs were 
prepared using an Illumina total prep RNA amplification kit (Applied Biosystems, Foster City, 
CA, USA). Briefly, 5ug of total RNA were converted to double stranded cDNA using T7-oligo 
(dT) primers and were followed by an in vitro transcription (IVT) reaction to amplify 
biotinylated cRNA as described in manufacturer’s instruction (Illumina Inc., San Diego, CA, 
USA). The biotinylated cRNA was hybridized to Rat Ref-12 Expression BeadChip platform that 
contains 22,519 probes (Illumina Inc., San Diego, CA, USA). The hybridization, washing and 
scanning were performed according to the manufacturer’s instructions. The chips were scanned 
using a BeadScan 2.3.0.10 (Illumina Inc., San Diego, CA, USA) at a multiplier setting of “2”. 
The microarray images were registered and extracted automatically during the scan using the 
manufacturer’s default settings. 
Microarray data analysis 
 
Image Quant software (Molecular Dynamics; Sunnyvale, CA) was used to convert the 
hybridization signals on the image into raw intensity values, and the data thus generated were 
transferred into MS Excel spreadsheets, predesigned to associate the Image Quant data format to 
the correct gene identities. Raw intensity data for each experiment was normalized by z 
transformation. Intensity data were first log10-transformed and used for the calculation of z 
scores. Z scores were calculated by subtracting the average gene intensity from the raw intensity 
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data for each gene and dividing that result by the S.D. of all the measured intensities. Gene 
expression differences between any two experiments were calculated by taking the difference 
between the observed gene z scores. The significance of calculated z differences can be directly 
inferred from measurements of the S.D. of the overall z difference distribution. Assuming a 
normal distribution profile, z differences are assigned significance according to their relation to 
the calculated standard deviation of all the z differences in any one comparison. To facilitate 
comparison of z difference between several different experiments, z differences were divided by 
the appropriate standard deviation to give the z ratios.  
Detection of differentially expressed genes  
 
The lists of significant differentially expressed genes were identified based upon the 
following screening criteria: 1) candidate gene expression should show at least 1.5 z-ratios, p-
value < 0.05, false recovery rate < 0.3 in rat UCMSC co-cultured with Mat B III cells; 2) 
candidate genes encode secretory proteins; and 3) candidate genes encode growth regulation-
related proteins. Further hierarchical cluster analysis was performed using open source softwares 
Cluster 3.0 and Java Treeview . 
Quantitative real time-polymerase chain reaction (qRT-PCR) 
 
Microarray results were validated by qRT-PCR using the same RNA samples as those 
used for the microarray. qRT-PCR was carried out using iScript One-Step RT-PCR Kit with 
SYBR Green (Bio-Rad, Hercules, CA) and the reactions were conducted on the real-time PCR 
detection system iCycler (Bio-Rad. Hercules, CA). The PCR was performed as follows: 45 
cycles with initial incubation at 94°C for 3 min and final extension at 72°C for 7 min. Each cycle 
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consisted of denaturation for 45 s at 94°C, annealing for 45 s at 58°C, and extension for 1 min at 
72 °C.  The results were quantified as Ct values, where Ct is defined as the threshold cycle of 
PCR at which the amplified product is first detected and signifies relative gene expression (the 
ratio of target/control). The primers used in this study are indicated in Table 2.1. 
[3H] Thymidine uptake assay 
 
In all [3H] thymidine incorporation experiments, rat UCMSC (0.25× 104 per well) were 
plated in 24-well culture plates and were cultured in CO2 incubator overnight. Neutralizing 
antibodies (4 µg per well) were added to the culture medium two hours prior to the co-culture 
with Mat B III cells (5 × 104 cells per well). Cells were cultured additional 24 h and pulsed for 
the last 4 h of the culture time with 1.0 µCi [3H] thymidine per well. Mat B III cells in 
suspension culture were collected, and the free-[3H] thymidine in the medium was washed away 
with PBS. The cell-incorporated [3H] thymidine was solubilized by adding 0.2 M NaOH and 
counted by the Packard liquid scintillation counter Tri-Carb 2100TR (Perkin-Elmer Life Science, 
Boston, MA, USA). 
Immunoprecipitation and Western blotting 
 
Rat UCMSC (0.25 × 106 cells per well) were seeded in a 10 cm culture dish and were 
cultured in CO2 incubator overnight. Mat B III cells ( 4 × 106 cells per well) were added to the 
rat UCMSC cells grown in 10 cm culture dish and further incubated for 24 h. Mat B III in 
suspension was removed and the culture medium was collected for further analysis. 
One ml of supernatant was pre-cleared with 30 µl of protein-A agarose resin slurry 
(50%)( Thermo Fisher Scientific, Rockford, IL) for 2 h at 4°C. Supernatant was collected into 
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new tubes by centrifugation at 13,000 rpm for 5 min at 4°C. Three µg/mL of respective gene 
specific neutralizing antibody was added and incubated overnight at 4°C with gentle rocking. 
Seventy µl of protein-A agarose resin slurry was added and incubated for 3-4h at 4°C. The beads 
(resin-antibody-protein complexes) were washed three times with ice-cold 1xTris buffered saline 
(TBS) by centrifugation at 6,500 rpm for 5 min. Protein-antibody complexes were eluted by 
suspending the Protein A Resin in 30µl of 2X sample loading buffer and boiled for 5 minutes. 
The samples were stored at -80°C for future use. 
Protein samples were separated by an 8 or 12 % SDS-PAGE gel, electroblotted onto 
nitrocellulose membrane (GE Healthcare Bioscience Corp, Piscataway, NJ) and blocked with 4% 
nonfat dry milk in 0.1% Tween20 in phosphate buffered saline (PBST) for 1hr at room 
temperature. The membranes were washed and incubated with specific antibodies against  
PDPN, ADRP and GPI (1:200, Santa Cruz Biotechnology) with 4% nonfat dry milk in PBST for 
1hr at room temperature and then with the secondary antibody (1:2000, GE Healthcare, 
Piscataway, NJ). The protein expression signal was detected with Pierce ECL Western Blotting 
substrate (Pierce, Rockford, IL). 
Statistical analysis 
 
Statistical analysis was conducted using student’s t-test in Microsoft Excel. The data 
were presented as mean ± SE. Experiments were performed at least three times with different 
batches of cells. Results were considered to be statistically significant at p ≤ 0.0 
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Table 2.1 
The list of the primers used for qRT-PCR 
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CHAPTER 3 - Results 
Screening of unique tumoricidal genes by cDNA microarray analysis 
 
To screen genes associated with rat UCMSC-dependent growth attenuation of rat 
mammary tumors, [18] genome-wide cDNA microarray analyses was carried out using an 
Illumina RatRef-12 Expression BeadChip which contains 22,519 distinctive rat cDNA 
oligonucleotide probes. Although this microarray chip does not contain whole rat genes, it 
encompasses the largest number of rat genes at the time of the analysis. In this study, total RNA 
was extracted from the rat UCMSC either co-cultured with (defined as stimulated UCMSC) or 
without Mat B III rat mammary adenocarcinoma cells (defined as unstimulated UCMSC) in the 
Transwell culture dish (two cell types were divided with a porous membrane with 0.4µm pores). 
Total RNA was reverse transcribed to cDNA. Hybridization with biotinylated cRNA transcribed 
from the cDNA was carried out in triplicate and gene expression profiles of rat UCMSC in two 
conditions were compared. As shown in the Figure 3.1, RNA quality was high enough for further 
microarray analysis.  For unique gene screening, the following criteria were set: 1) candidate 
gene expression should show at least a 1.5 fold change in rat UCMSC co-cultured with Mat B III 
cells; 2) candidate genes must encode secretory proteins; and 3) candidate genes should encode 
positive or negative cell growth-related proteins. Data analysis by Z-normalization of the 
hybridization signals identified sixteen differentially expressed genes in two culture conditions, 
i.e. their expressions were at least 1.5 fold different (Figure 3.2). Nine of these genes were up 
regulated in rat UCMSC when co-cultured with the Mat B III cells and seven of these genes were 
down regulated (Figure 3.3). Among these genes, a total of five up-regulated (HTRA1, SULF1, 
GPI, ADRP, and FST) and two down-regulated genes (TGFβI and PDPN) were further 
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characterized as candidate genes associated with growth regulation of tumor cells, i.e. these 
genes encoding secretory proteins and associated with cell growth regulation.  
The mRNA expressions of these seven genes in rat UCMSC were verified by a qRT-PCR 
using the total RNA extracted for microarray analysis. Of the five up regulated genes selected 
from microarray analysis, all five genes showed concordant results between microarray analysis 
and qRT-PCR. However, although PDPN and TGFβI showed a significantly decreased 
expression in microarray analysis, their expressions were detected to be identical to the un-
stimulated rat UCMSC levels (Figure 3.4). These results indicate that the data obtained from 
qRT-PCR correlate well with the microarray results. Results from both analyses suggest that the 
sensitivity of the two methods appears to be different in each gene. However, the qRT-PCR 
method may be more sensitive than the microarray. It is important to note that the fold change 
obtained by the qRT-PCR assays was bigger than z-ratios in the array data. This is because the z-
ratios are z-differences divided by standard deviation and not fold change ratios. As shown in 
Table 3.1 below , out of the seven genes, six genes, HTRA1, SULF1, GPI, ADRP, FST and 
TGFβI, have been characterized as tumor suppressor genes, whereas one PDPN gene  has been 
identified as tumor promoter gene. Based on the extent of the differential expression and 
individual characterization of these genes, SULF1, GPI, and ADRP were further studied to 
determine their roles in the rat UCMSC-dependent tumor growth attenuation. 
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Effect of neutralizing antibodies specific to selected candidate genes on the 
DNA synthesis in mammary carcinoma cells  
 
In the initial experimental optimization study, it was found that a small number of rat 
UCMS cells (0.25 × 104) most significantly inhibited [3H] thymidine uptake by Mat B III cells (5 
× 104) when they were co-cultured together (rat UCMSC:Mat B III = 1:20, Figure 3.5). 
Accordingly, this condition was utilized for the following experiment. 
Decrease in the rat UCMSC-dependent inhibition of [3H] thymidine uptake by individual 
neutralizing antibodies against SULF-1, GPI or ADRP suggested that all three genes play a role 
in the tumor growth attenuation by rat UCMSC (Figure 3.6). We further investigated the effect 
of all three neutralizing antibodies added together to the culture medium for rat UCMSC co-
culturing with Mat BIII cells. Adding three antibodies together markedly increased [3H] 
thymidine uptake in Mat B III cells (Figure 3.7). This result suggests that these neutralizing 
antibodies appear to attenuate tumor suppressor protein function individually. As a control 
experiment the rat UCMSC were co-cultured with Mat B III cells in the presence of anti-decorin 
antibody (an un-related gene to rat UCMSC-dependent growth inhibition) (Figure 3.8). This is 
consistent with the original hypothesis that rat mammary carcinoma cell stimulated genes in rat 
UCMSC are responsible for growth regulation of Mat B III. 
As a control study, rat UCMSC were substituted with rat uterus fibroblasts. However, rat 
uterus fibroblasts did not show any growth attenuation of Mat B III cells (data not shown). This 
result clearly suggests that rat UCMSC-dependent attenuation of mammary tumor cell growth is 
an UCMSC-specific event. 
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Detection of candidate gene products in culture medium by Western blot 
analysis 
 
To confirm all three gene products are indeed secreted out and play tumor suppressor 
roles in adjacent tumor cells, presence of all three proteins in the culture medium was analyzed 
by Western blot analysis. For this purpose, secreted proteins were collected from the culture 
medium by immunopreciptation as described in the Methods. As shown in the Figure 3.9, all 
three gene products were detected in the culture media conditioned with the rat UCMSC alone, 
Mat B III cells alone, and two cell types together. Although these protein levels were higher in 
the medium used for the co-culture, it was difficult to compare their expressions due to a 
technical difficulty of normalization with loading standard. However, these results support our 
hypothesis that tumor suppressor proteins are produced by rat UCMSC, secreted out from the 
cells and play role in the control of tumor growth.  
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Table 3.1 
Functions of differentially expressed genes. 
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Figure 3.1 
Quality analysis of total RNA obtained from rat UCMSC alone and rat UCMSC co-
cultured with Mat BIII group. Totally three RNA samples were prepared for each group. As 
the z-score in the correlation table shows, both rat.UCMSC (RUC) and rat UCMSC co-cultured 
with Mat B III (co-RUC) groups have high quality of RNA. 
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Figure 3.2 
Gene clustering of secretory protein encoding genes. Expression levels of mRNA (z-
score) of rat UCMSC alone, Mat B III alone and rat UCMSC co-cultured with Mat BIII (co-
UCMSC). Highlighted genes were further characterized. 
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Figure 3.3  
Z-ratio of differentially expressed genes in rat UCMSC co-cultured with Mat B III 
cells. Total RNA was extracted from rat UCMSC 24 hour after co-culturing with or without Mat 
B III rat mammary carcinoma cells. Co-culture was carried out in the Transwell culture dish so 
that two types of cells were not mixed each other. Microarray analysis was performed as 
described in the Methods to identify differentially expressed genes in rat UCMSC co-cultured 
with or without the rat mammary adenocarcinoma cells. 
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Figure 3.4 
Fold changes of differentially expressed genes in the rat UCMSC co-cultured with 
or without Mat B III cells in qRT-PCR analysis of candidate genes selected initially by 
microarray analysis. Half shaded bars indicate Z-ratios analyzed by microarray analysis. Dark 
solid bars represent fold changes determined by real time PCR analysis. 
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Figure 3.5   
Optimization of the cell ratio of rat UCMSC to Mat B III cells for [3H] thymidine 
uptake assay. In order to evaluate the most appropriate growth inhibition of Mat B III by rat 
UCMSC both cells were co-cultured at various ratios as indicated in the figure. [3H]-thymidine 
uptake was determined at 24 hrs after co-culturing of both cell types. Each value represents 
means ± SE of three independent experiments. *, P < 0.05, compared with rat UCMSC alone or 
Mat B III alone.  
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Figure 3.6  
The effect of neutralizing antibodies against ADRP (ADFP), SULF-1 and GPI on 
cell proliferation of Mat B III cells co-cultured with rat UCMSC. [3H]-thymidine uptake was 
determined at 24 hrs after co-culturing rat UCMSC with Mat B III cells in the presence or 
absence of anti-ADRP (left column), SULF-1(middle column) and GPI (right column) antibodies 
(4 µg/well). Each value represents means ± SE of three independent experiments. *, P value < 
0.05, compared with thymidine uptake by Mat B III cells co-cultured with rat UCMSC. 
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Figure 3.7 
The effect of neutralizing antibody cocktail against ADRP, SULF-1 and GPI on cell 
proliferation of Mat B III cells co-cultured with rat UCMSC. [3H]-thymidine uptake assay 
was determined at 24 hrs after co-culturing rat UCMSC with Mat B III cells in the presence or 
absence of anti-ADRP, SULF-1 and GPI antibodies. Each value represents means ± SE of three 
independent experiments. *, P value < 0.05, compared with Mat B III cells co-cultured with rat 
UCMSC.  
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Figure 3.8 
The effect of neutralizing antibody against tumor suppressor decorin on cell 
proliferation of Mat B III cells co-cultured with or without rat UCMSC. The rat UCMSC 
were co-cultured with Mat B III cells in presence or absence of polyclonal rabbit antibody 
against Decorin. Since gene expression of decorin in rat UCMSC was unchanged when co-
cultured with Mat B III cells; this tumor suppressor gene was used as a control gene. Each value 
represents means ± SE of three independent experiments. *, P value < 0.05, compared with Mat 
B III cells co-cultured with rat UCMSC.  
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Figure 3.9  
Detection of PDPN, ADRP and GPI in the culture medium by Western blot analysis. 
Rat UCMSC and Mat B III cells were either cultured individually or co-cultured together in 
defined medium. Three gene products were immunoprecipitated using specific polyclonal rabbit 
antibody against PDPN and polyclonal goat antibodies against ADRP and GPI. Each 
immunoprecipitates were subjected to PAGE and then immunoblotted using specific monoclonal 
antibody for PDPN or polyclonal antibodies for ADRP and GPI. Lane1, immunoprecipitated 
protein from the medium cultured with rat UCMSC alone; lane2, immunoprecipitated proteins 
from the medium cultured with Mat B III cells alone; lane 3, immunoprecipitated proteins from 
the medium co-cultured rat UCMSC and Mat B III cells at the ratio of 1 to 8. 
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CHAPTER 4 - Discussion 
 
Increasing evidence suggests that adult stem cells can be effective therapeutic tools for 
various diseases including cancer [17, 18, 20, 21, 36]. Indeed, multiple adult stem cells 
engineered to express therapeutic genes have been reported to be very effective in attenuating 
various cancers [17, 38, 41]. A few papers have also reported that naïve adult stem cells have an 
intrinsic ability to attenuate growth of several types of cancer cells such as Kaposi’s sarcoma and 
glioma [51-53]. Our colleagues have also reported that un-engineered rat UCMSC attenuate rat 
mammary carcinoma [18] and mouse pancreatic carcinoma [37] in immunocompetent animals. A 
drawback of cancer cytotherapy using engineered stem cells is unexpected gene expression of 
the transfected gene or, if viral vectors are used, mutation of the vector genes into a virulent form 
or insertion into inappropriate genomic regions[36]. Thus, if naïve stem cells can be used for 
cancer cytotherapy, the safety of cytotherapy will be increased significantly. 
Accordingly, the aim of the present study was to determine the molecular mechanism of 
the intrinsic tumoricidal activity in rat UCMSC. In the present study, we identified potential 
genes involved in the intrinsic tumoricidal ability of rat UCMSC for rat malignant breast 
carcinoma cells in vitro. The study provides strong evidence that multiple tumor suppressor 
genes are involved in rat UCMSC-dependent tumoricidal activity. This evidence can be utilized 
for future development of a safe cancer-targeted cytotherapy for breast carcinoma.  
First, we screened for potential genes involved in the rat UCMSC-dependent tumoricidal 
activity using cDNA microarray analysis. The microarray analysis provides the means to 
perform parallel analysis of genome-wide genes in a single assay resulting in a semi quantitative 
assessment of changes in mRNA expression. Although the Illumina RatRef-12 Expression 
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BeadChip used for this study does not cover entire genome-wide genes, this was the only 
available rat microarray chip that covers a larger number of rat genes. From our cDNA 
microarray analysis we screened only 16 significant genes which are differentially expressed in 
the rat UCMSC when they were co-cultured for 24 hours with Mat B III rat mammary carcinoma 
cells (Figure 3.3). Among these 16 genes, seven genes were further screened based on the criteria 
that they should produce secretory proteins and their gene products should be involved in tumor 
growth regulation (Figure 3.4). Accordingly, seven of the genes screened are differentially 
expressed; their products are secreted and reported to play a role in cell growth regulation. 
Differential expression of these seven genes was further confirmed by qRT-PCR using the same 
RNA samples (Figure 3.4). A remarkable finding in this screening was that six genes are known 
tumor suppressor genes and one gene is a tumor promoter gene. Up-regulation of multiple tumor 
suppressor genes in rat UCMSC is a conceivable and reasonable event since our colleagues have 
found that rat UCMSC, significantly attenuate tumor growth in vivo and in vitro [18, 37]. 
Therefore, screening of the intrinsic tumoricidal genes in rat UCMSC by genome wide 
microarray and confirming their expressions by qRT-PCR analysis appears to have been 
successfully conducted.  
Among seven genes screened, ADRP, SULF-1, and GPI exhibited highest up-regulation 
when rat UCMSC were co-cultured with mammary carcinoma cells. Accordingly, these three 
genes were further characterized by their potential tumor suppressor function. For this 
characterization purpose, [3H] thymidine uptake assay was utilized since this assay is a sensitive 
evaluation of cell proliferation.  As described in the results, individual neutralizing antibodies 
against three gene products significantly increased [3H] thymidine uptake by Mat B III cells co-
cultured with rat UCMSC (Figure 3.6). When all three antibodies were added simultaneously in 
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the culture medium, this increase was markedly pronounced not only in co-cultured Mat B III 
cells but also in Mat B III cells alone (Figure 3.7). These results strongly suggest that these three 
gene proteins are secretory and attenuate cell proliferation of Mat B III cells. Negative control 
experiments confirmed that the effect of these neutralizing antibodies was specific to these three 
tumor suppressor proteins since a neutralizing antibody against tumor suppressor protein 
(irrelevant, non-differentially expressed) decorin and control IgG did not show any effect on [3H] 
thymidine uptake by Mat B III cells. Furthermore, co-culturing rat uterus fibroblasts did not 
exhibit any effect on Mat B III cell proliferation (Data not shown). Product secretion from the 
three identified genes was confirmed by immunoprecipitation of the proteins in the culture 
medium and resultant Western blot analysis (Figure 3.9). These results strongly suggest that the 
tumoricidal effect of rat UCMSC is specific and at least, in part, carried out by up-regulation of 
multiple tumor suppressor genes.  Although Larmonier et al have reported that nitric oxide plays 
a significant role in bone marrow mesenchymal stem cell-induced growth alteration of cancer 
cells [53], rat UCMSC-dependent growth attenuation may not be due to nitric oxide since nitric 
oxide is very unstable in culture media [54]. 
In summary, the present study demonstrates that rat UCMSC significantly attenuates 
growth of Mat B III rat mammary carcinoma cells in culture. Rat UCMSC-dependent tumor cell 
growth attenuation is associated with up-regulation of multiple tumor suppressor genes in rat 
UCMSC. These tumor suppressor proteins were shown to be secretory regulators of tumor cell 
proliferation. These results clearly suggest that naïve rat UCMSC is a potential cytotherapeutic 
tool for breast cancer therapy.  
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